IP STRATEGY


STRINGS TO ITS BOW


TWO


At fi rst glance, it might seem odd for a company to both divide blood plasma and


fi ght the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the


company does it and also protects its IP.


D


uring World War II, as soldiers struggled to cope with injuries sustained in battle, a man called Edwin Cohn created a


solution to help them recover.


T e scientist invented the fi rst practical method of what is known as blood plasma fractionation, where the conditions of pooled plasma (for example, temperature or acidity) are changed so that proteins that are normally dissolved become insoluble, aiding a speedy recovery.


At the time, the method, known as the Cohn process, was hailed as revolutionary. But fast- forward 70 years and a US company thinks it has found a new solution that will be a game-changer, and has patented it.


PlasmaTech Biopharmaceuticals develops plasma- derived therapeutics, including its own plasma fractionation process, as well as hydrogel products used for treating the side eff ects of cancer.


Explaining its new fractionation system, PlasmaTech’s chief executive Scott Schorer tells


14 Life Sciences Intellectual Property Review Volume 2, Issue 1 www.lifesciencesipreview.com


EVERETT COLLECTION / SHUTTERSTOCK.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44